Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Emerging science of hydroxyurea therapy for pediatric sickle cell disease.

Pediatric research - 1 Jan 2014

Green Nancy S, Barral Sandra

Abstract excerpt

Hydroxyurea (HU) is the sole approved pharmacological therapy for sickle cell disease (SCD). Higher levels of fetal hemoglobin (HbF) diminish deoxygenated sickle globin polymerization in vitro and clinically reduce the incidence of disease morbidities. Clinical and laboratory effects of HU largely result from induction of HbF expression, though to a highly variable extent. Baseline and HU-induced HbF expression...

Topics

Age Factors
Anemia, Sickle Cell
Animals
Antisickling Agents
Child
Child, Preschool
Fetal Hemoglobin
Genetic Markers
Genetic Predisposition to Disease
Humans
Hydroxyurea
Infant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Infant, Newborn

Phenotype

Polymorphism, Single Nucleotide

Risk Factors

Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 24252885
DOI: 10.1038/pr.2013.227
PMCID: PMC3917141

Genes

SCD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging science of hydroxyurea therapy for pediatric sickle cell disease.PMID 24252885Read ↗

Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.Semantic proximity Read ↗

Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemiaSemantic proximity Read ↗

Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.Semantic proximity Read ↗

A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.Semantic proximity Read ↗

Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.Semantic proximity Read ↗

Reviewing the impact of hydroxyurea on DNA methylation and its potential clinical implications in sickle cell diseaseSemantic proximity Read ↗

Modeling Genetic Diversity in Sickle Cell Disease Reveals Heterogeneous Responses to HbF-Inducing TherapiesSemantic proximity Read ↗

Research in Sickle Cell Disease: From Bedside to Bench to BedsideSemantic proximity Read ↗

A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapySemantic proximity Read ↗

The role of BCL11A and HMIP-2 polymorphisms on endogenous and hydroxyurea induced levels of fetal hemoglobin in sickle cell anemia patients from southern Brazil.Semantic proximity Read ↗

Optimizing hydroxyurea therapy for sickle cell anemia.Semantic proximity Read ↗

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.